Skip to main content

AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines

AstraZeneca shares jumped 3% after the Anglo-Swedish drugmaker said it expects its full-year revenues will increase at a higher rate than previously forecast
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.